Stephen Christopher Linthwaite Acquires 45,000 Shares of Fluidigm Corporation (NASDAQ:FLDM) Stock

Fluidigm Corporation (NASDAQ:FLDM) CEO Stephen Christopher Linthwaite acquired 45,000 shares of Fluidigm Corporation stock in a transaction on Tuesday, August 8th. The stock was purchased at an average price of $2.66 per share, with a total value of $119,700.00. Following the transaction, the chief executive officer now directly owns 106,977 shares in the company, valued at approximately $284,558.82. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Fluidigm Corporation (FLDM) traded up 14.02% during mid-day trading on Tuesday, hitting $3.09. The company’s stock had a trading volume of 873,968 shares. Fluidigm Corporation has a 1-year low of $2.52 and a 1-year high of $9.65. The company’s market cap is $90.52 million. The company has a 50-day moving average of $3.84 and a 200 day moving average of $5.08.

Fluidigm Corporation (NASDAQ:FLDM) last posted its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative return on equity of 104.38% and a negative net margin of 74.05%. The company had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.50 million. During the same quarter in the prior year, the business earned ($0.63) earnings per share. The firm’s revenue for the quarter was down 15.2% on a year-over-year basis. On average, analysts expect that Fluidigm Corporation will post ($2.19) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Stephen Christopher Linthwaite Acquires 45,000 Shares of Fluidigm Corporation (NASDAQ:FLDM) Stock” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/stephen-christopher-linthwaite-acquires-45000-shares-of-fluidigm-corporation-nasdaqfldm-stock/1409947.html.

Several institutional investors have recently bought and sold shares of FLDM. Metropolitan Life Insurance Co. NY increased its position in Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock valued at $151,000 after buying an additional 632 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock valued at $144,000 after buying an additional 1,013 shares during the last quarter. American International Group Inc. increased its position in Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock valued at $102,000 after buying an additional 1,187 shares during the last quarter. Falcon Point Capital LLC increased its position in Fluidigm Corporation by 3.1% in the first quarter. Falcon Point Capital LLC now owns 40,661 shares of the medical research company’s stock valued at $231,000 after buying an additional 1,238 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Fluidigm Corporation by 1.5% in the first quarter. Geode Capital Management LLC now owns 218,321 shares of the medical research company’s stock valued at $1,242,000 after buying an additional 3,311 shares during the last quarter. 91.66% of the stock is currently owned by institutional investors.

FLDM has been the subject of a number of research reports. Zacks Investment Research downgraded Fluidigm Corporation from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm Corporation (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras


Leave a Reply

 
© 2006-2017 BBNS.